MX2023001566A - Compuesto para dirigirse a una proteina y degradarla, y método de preparación del mismo y uso del mismo. - Google Patents
Compuesto para dirigirse a una proteina y degradarla, y método de preparación del mismo y uso del mismo.Info
- Publication number
- MX2023001566A MX2023001566A MX2023001566A MX2023001566A MX2023001566A MX 2023001566 A MX2023001566 A MX 2023001566A MX 2023001566 A MX2023001566 A MX 2023001566A MX 2023001566 A MX2023001566 A MX 2023001566A MX 2023001566 A MX2023001566 A MX 2023001566A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- preparation
- targeting
- method therefor
- irak4
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 230000000593 degrading effect Effects 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 238000001814 protein method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 abstract 2
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 abstract 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente invención se proporciona una clase de compuestos bifuncionales para dirigirse a una proteína quinasa IRAK4 y degradarla, una composición farmacéutica y un método de preparación de la misma. El compuesto de la presente invención no solo puede inhibir o degradar de manera eficaz la proteína quinasa IRAK4 en las células, sino que también puede inhibir de manera eficaz la producción de IL-6 por parte de las células inmunitarias y tiene una buena selectividad de degradación. El compuesto puede usarse en la preparación de un fármaco para tratar o prevenir enfermedades o afecciones relacionadas mediadas por IRAK4, tales como el cáncer, enfermedades inmunológicas y enfermedades inflamatorias.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010785541 | 2020-08-05 | ||
| CN202011513669 | 2020-12-18 | ||
| PCT/CN2021/110990 WO2022028547A1 (zh) | 2020-08-05 | 2021-08-05 | 靶向蛋白降解化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001566A true MX2023001566A (es) | 2023-04-13 |
Family
ID=80117051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001566A MX2023001566A (es) | 2020-08-05 | 2021-08-05 | Compuesto para dirigirse a una proteina y degradarla, y método de preparación del mismo y uso del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230234936A1 (es) |
| EP (1) | EP4194457A1 (es) |
| JP (1) | JP2023530848A (es) |
| KR (1) | KR20230050375A (es) |
| CN (2) | CN115244053B (es) |
| AU (1) | AU2021323304A1 (es) |
| BR (1) | BR112023002112A2 (es) |
| CA (1) | CA3188258A1 (es) |
| MX (1) | MX2023001566A (es) |
| TW (1) | TWI833104B (es) |
| WO (1) | WO2022028547A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115710274A (zh) * | 2021-08-23 | 2023-02-24 | 上海领泰生物医药科技有限公司 | Irak4降解剂及其制备方法和应用 |
| WO2024094190A1 (zh) * | 2022-11-04 | 2024-05-10 | 上海领泰生物医药科技有限公司 | Irak4降解剂及其用途 |
| CN117024413B (zh) * | 2023-10-07 | 2024-01-09 | 天津匠新致成科技有限公司 | 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201614134D0 (en) * | 2016-08-18 | 2016-10-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MX2019009046A (es) * | 2017-01-31 | 2019-10-30 | Arvinas Operations Inc | Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo. |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| WO2019160915A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| JP2022516401A (ja) | 2018-11-30 | 2022-02-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
-
2021
- 2021-08-05 WO PCT/CN2021/110990 patent/WO2022028547A1/zh active Application Filing
- 2021-08-05 AU AU2021323304A patent/AU2021323304A1/en active Pending
- 2021-08-05 JP JP2022573195A patent/JP2023530848A/ja active Pending
- 2021-08-05 BR BR112023002112A patent/BR112023002112A2/pt unknown
- 2021-08-05 MX MX2023001566A patent/MX2023001566A/es unknown
- 2021-08-05 CN CN202180018078.4A patent/CN115244053B/zh active Active
- 2021-08-05 US US17/999,798 patent/US20230234936A1/en active Pending
- 2021-08-05 EP EP21852332.2A patent/EP4194457A1/en active Pending
- 2021-08-05 TW TW110128949A patent/TWI833104B/zh active
- 2021-08-05 CN CN202410106573.6A patent/CN117964623A/zh active Pending
- 2021-08-05 CA CA3188258A patent/CA3188258A1/en active Pending
- 2021-08-05 KR KR1020237007867A patent/KR20230050375A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| TW202210470A (zh) | 2022-03-16 |
| AU2021323304A1 (en) | 2023-03-02 |
| WO2022028547A1 (zh) | 2022-02-10 |
| EP4194457A1 (en) | 2023-06-14 |
| US20230234936A1 (en) | 2023-07-27 |
| KR20230050375A (ko) | 2023-04-14 |
| CA3188258A1 (en) | 2022-02-10 |
| CN115244053A (zh) | 2022-10-25 |
| CN117964623A (zh) | 2024-05-03 |
| JP2023530848A (ja) | 2023-07-20 |
| BR112023002112A2 (pt) | 2023-04-18 |
| TWI833104B (zh) | 2024-02-21 |
| CN115244053B (zh) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001566A (es) | Compuesto para dirigirse a una proteina y degradarla, y método de preparación del mismo y uso del mismo. | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| MX2020010407A (es) | Benzotiofenos y compuestos relacionados como agonistas de sting. | |
| CA2999253C (en) | Heterocyclic compounds and uses thereof | |
| PH12017500367B1 (en) | Compounds that inhibit mcl-1 protein | |
| EP4292662A3 (en) | Substituted indole mcl-1 inhibitors | |
| MX2023002507A (es) | Inhibidores de cd73. | |
| MX2023008716A (es) | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| WO2019152419A8 (en) | Prc2 inhibitors | |
| MX2020010805A (es) | Inhibidores de bcl6. | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| MX2021009868A (es) | Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. | |
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551891A1 (en) | New quinoline derivatives | |
| WO2018038988A3 (en) | Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them | |
| ZA202109179B (en) | Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
| WO2017098051A3 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
| WO2017165822A8 (en) | Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | |
| ZA202308118B (en) | Cdk inhibitor | |
| MX2021008712A (es) | Derivados heterociclicos. |